PHARNEXT SCA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1718 EUR | +14.76% |
|
-5.60% | -91.41% |
| Mar. 06 | Pharnext: listing suspended pending further update | CF |
| Feb. 21 | Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing... |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
Sector
Pharmaceuticals
Calendar
2024-10-16
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -91.41% | 27.76K | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- ALPHA Stock
- News Pharnext SCA
- Pharnext : Enrolls First Patient in European Phase 3 Study of Rare Genetic Disorder Drug
